Veterinary Medicinal Products
The EU regulation governing the authorisation, manufacture, import, distribution, and pharmacovigilance of veterinary medicinal products. Applying since January 2022, it replaced Directive 2001/82/EC, expanded scope (including euthanasia substances), and substantially strengthened provisions to combat antimicrobial resistance.
What this does not cover
stated in the document's own scope- Covers veterinary medicinal products; medicated feed is addressed in the linked Regulation (EU) 2019/4, and human medicines fall under Directive 2001/83/EC and Regulation (EC) No 726/2004.
- Governs authorisation, manufacture, distribution and pharmacovigilance, not the detailed GMP technical text itself, which follows the GMP principles of the EU GMP Guide.
- Sets the veterinary regulatory framework, not the general animal-health or feed-hygiene law that sits in separate EU instruments.
- Applies EU-wide as a directly applicable regulation, so Member States do not create their own veterinary-medicines codes in its place.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Regulation (EU) 2019/6 governs veterinary medicinal products across the EU — their authorisation, manufacture, import, distribution, supply, use and pharmacovigilance. It modernised and consolidated the EU veterinary framework into a single directly applicable regulation, simplified marketing-authorisation procedures, established EU product and manufacturer databases, and reduced administrative burden while expanding the framework’s scope. A central theme is the fight against antimicrobial resistance: the regulation restricts prophylactic and metaphylactic antimicrobial use, allows certain antimicrobials to be reserved for human medicine, and adds controls on medicated feed and on the import of treated animals and products.
Scope & applicability
Veterinary medicinal products across the EU market — from manufacturing authorisation and GMP through distribution and safety surveillance.
Legal basis & how it acquires force
This is a Regulation, so it applies directly in all Member States without transposition. It repealed and replaced Directive 2001/82/EC, the earlier veterinary medicines directive, precisely to remove the divergence that separate national implementations had caused. Adopted in 2018, it became applicable on 28 January 2022, with several of its detailed rules fleshed out by Commission implementing and delegated acts. Its manufacturing provisions require GMP compliance and a manufacturing authorisation, aligning veterinary manufacture with the GMP principles used for human medicines.
Document structure
| Part | Covers |
|---|---|
| Marketing authorisation | Authorisation procedures, dossier requirements, and the product database |
| Manufacture, import and GMP | Manufacturing and import authorisation and compliance with good manufacturing practice |
| Antimicrobial provisions | Restrictions on prophylaxis/metaphylaxis, reserved antimicrobials, and use controls |
| Distribution, supply and use | Wholesale and retail supply, prescription rules, and conditions of use |
| Pharmacovigilance | The pharmacovigilance system, signal management, and the EU pharmacovigilance database |
| Controls and enforcement | Member-State supervision, inspections, and enforcement measures |
Key requirements
- Hold appropriate manufacturing/import authorisation and comply with veterinary GMP
- Operate a pharmacovigilance system for veterinary medicines
- Apply antimicrobial-resistance controls and use restrictions
- Meet EU product-database and traceability obligations
Implementation tips
- Prioritise the antimicrobial-resistance provisions — they are the regulation’s signature change
- Stand up veterinary pharmacovigilance distinct from your human-medicine GVP where both apply
- Confirm database/traceability submissions; they are a new compliance surface
Revision notes
Adopted December 2018 and applicable since 28 January 2022, replacing Directive 2001/82/EC with expanded scope and stronger antimicrobial-resistance measures.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The regulation is the veterinary counterpart to the EU human-medicines framework, and its manufacturing provisions apply GMP principles equivalent to those in the EU GMP Guide. On technical requirements it draws on VICH, the international veterinary harmonisation body whose guidelines (for example on stability and safety testing) the EU adopts. Its antimicrobial-resistance focus aligns EU veterinary policy with the wider One Health agenda pursued internationally.
Regulation (EU) 2019/6: frequently asked questions
Quick answers to common questions about Regulation (EU) 2019/6.
What did Regulation (EU) 2019/6 replace?
It replaced Directive 2001/82/EC, the previous EU veterinary medicines directive. Because it is a Regulation, it applies directly in every Member State, removing the divergence caused by national transpositions of the old directive.
When did the Veterinary Medicinal Products Regulation become applicable?
Regulation (EU) 2019/6 was adopted in 2018 and became applicable on 28 January 2022, with detailed rules set out in accompanying Commission implementing and delegated acts.
How does the regulation address antimicrobial resistance?
It restricts prophylactic and metaphylactic antimicrobial use, permits certain antimicrobials to be reserved for human medicine, tightens rules on medicated feed, and extends controls to animals and products imported into the EU — making antimicrobial-resistance prevention a central objective of the framework.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.